INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia

Despite the limitations of retrospective studies, the INO-CD22 study highlights the favorable safety profile and clinical activity of IO within a real-world context.

Authors

Institutions

Publication Details

Journal
Cancer
Published
2025-03-22
DOI
https://doi.org/10.1002/cncr.35820
Citations
2
Primary Topic
Acute Lymphoblastic Leukemia research
Type
article
Field-Weighted Citation Impact
3.76

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia

Federica Frabetti, Daniele Giovanni Mattei, Elisa Roncoroni, Mario Luppi et al.
2 citations
Cancer
Acute Lymphoblastic Leukemia research
3.76
article

INO‐CD22: A multicenter, real‐world study of inotuzumab ozogamicin safety and effectiveness in adult patients with relapsed/refractory acute lymphoblastic leukemia

Federica Frabetti, Daniele Giovanni Mattei, Elisa Roncoroni, Mario Luppi, Francesco Passamonti, Nicola Di Renzo, Nicola Fracchiolla, Elisabetta Todisco, Chiara Sartor, Michele Gottardi, Francesco Lanza, Chiara Zingaretti, Giovanni Marconi, Fabio Ciceri, Fara Petruzziello, Erika Borlenghi, Elisabetta Petracci, Roberta Volpi, Francesco Di Raimondo, Felicetto Ferrara, Cristina Papayannidis, Maria Ilaria Del Principe, Daniele Vallisa, Paolo de Fabritiis, Paolo Corradini, Fabrizio Pane, Patrizia Zappasodi, Giovanni Martinelli, Maria Benedetta Giannini, Francesco Fabbiano, Monica Fumagalli, Simona Sica, Greta Mambelli
article en
2 citations

Abstract

Despite the limitations of retrospective studies, the INO-CD22 study highlights the favorable safety profile and clinical activity of IO within a real-world context.

CancerVol. 131(7)
University of Rome Tor Vergata (IT), University of Modena and Reggio Emilia (IT), Vita-Salute San Raffaele University (IT), University of Milan (IT), University of Pavia (IT), Ospedale di Circolo e Fondazione Macchi (IT), Agostino Gemelli University Polyclinic (IT), Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (IT), University of Catania (IT), Ospedale Antonio Cardarelli (IT), Ospedale "Santa Maria delle Croci" di Ravenna (IT), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), Ospedale Vincenzo Cervello (IT), Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (IT), Federico II University Hospital (IT), Istituto di Ematologia di Bologna (IT), Azienda Sanitaria Ospedaliera S.Croce e Carle Cuneo (IT), Guglielmo da Saliceto Hospital (IT), St. Eugenio Hospital (IT), Ca' Foncello Hospital (IT), Ospedale Vito Fazzi (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Aziende Socio Sanitarie Territoriale dei Sette Laghi, European Institute of Oncology (IT), University of Milano-Bicocca (IT)
Ministero della Salute
Good health and well-being
Openalex Percentile: Top 9%
Acute Lymphoblastic Leukemia research
3.76
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.